Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

Articles

Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.

Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better

Expanding coverage and access to glucagon-like peptide-1 (GLP-1) medication can be beneficial for all with the cooperation of multiple parties in health care.

Contributor: How Can the US Health Care System Affordably and Fairly Expand GLP-1 Access for the Millions of People Who Need it?

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

The 2025 American Academy of Dermatology (AAD) Annual Meeting introduces over 50 new sessions and debuts an opening ceremony, featuring a fireside chat with lifestyle expert and entrepreneur Martha Stewart.

2025 AAD Annual Meeting Debuts New Sessions, Opening Ceremony

The US Multi-Society Task Force updates 2014 recommendations, emphasizing split-dose prep, diet flexibility, and quality tracking.


Updated Guidelines Refine Best Practices for Colonoscopy Bowel Prep

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Optimizing Management of Metastatic Colorectal Cancer: Pharmacists’ Evolving Role and Overcoming Access Challenges 

Video Series

Third-Line Treatment Options in mCRC: A Clinical Overview

Video content above is prompted by the following:

Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens.

Trifluridine + tipiracil ± bevacizumab

Videos

Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC), assess the evolving role of pharmacists in treatment optimization and patient education, and analyze access challenges to mCRC therapies, proposing strategies to improve patient access.

Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.

Treatment Options in mCRC: A Clinical Overview

Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.

Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

Treatment Options in mCRC: A Clinical Overview

EP: 1.Treatment Options in mCRC: A Clinical Overview

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC